Levy C, et al. – In this assessment, the physicians explored the impact of 13–valent pneumococcal conjugate vaccine (PCV13) on community–acquired pneumonia (CAP) by C–reactive protein (CRP) and procalcitonin levels (PCT) in children. They discovered that PCV13 implementation had a strong impact on the number of CAP cases with high levels of CRP and/or PCT in children, however, had no impact on that with low levels of these two biomarkers. A sustained reduction in CAP cases was reported, after five years of PCV13 implementation.